Schering Corporation

Merck Sharp + Dohme Corp.

University of Pittsburgh

Mayo Foundation for Medical Education and Research

Pharmacopeia Drug Discovery, Inc.

Intervet Inc.

Mochida Pharmaceutical Co., Ltd.

Intervet International B.v.

Merck Canada Inc.

Schering-plough Corporation

Yan Xia

Samuel Chackalamannil

Mariappan Chelliah

William J Greenlee

Martin C Clasby

Andrew William Stamford

Craig D Boyle

Yuguang Wang

Alan P Kozikowski

Jared N Cumming

Bernard R Neustadt

Tao Guo

Ying Huang

Corey Strickland

Ulrich Iserloh

Deen Tulshian

Suresh D Babu

Yusheng Wu

Douglas Walsh Hobbs

Tin-Yau Chan

Kurt William Saionz

Thuy X H Le

Michael P Dwyer

Unmesh G Shah

Neil A Lindo

Lisa S Silverman

Brian Alexander McKittrick

Wenxue Wu

Zhuyan Guo

Santhosh Francis Neelamkavil

Theodros Asberom

Johannes H Voigt

Yongxin Han

Duane A Burnett

Hubert B Josien

Jack D Scott

Srikanth Venkatraman

Xing Dai

Hong Liu

Charles Jayne

Enrico P Veltri

Keith A Eagen

Fumihiko Saitoh

Michael F Czarniecki

Hidemitsu Nishida

Tomokazu Hirabayashi

Johannes H Voight

Jeffrey F Lowrie

Dario Doller

Jeffrey H Lowrie

Patrick A Pinto

Kartik M Keertikar

Linda Brockunier

Shouwu Miao

Francisco Velazquez

Joel M Harris

Thomas A Bara

Austin Chen

Sathesh P Bhat

Jinsong Hao

Henry M Vaccaro

Michael P Graziano

Murali Rajagopalan

Dipshikha Biswas

Haiyan Pu

Karen M Marcantonio

Li Wang

Xiaobang Gao

Teddy Kosoglou

Vince J Colandrea

Liyuan Wang

Keith Eagan

Madhu Chintala

Charles L Jayne

Mariappan V Chelliah

Yuguguang Wang

Samuel Cackalamannil

Marriappan Chelliah

Li Yuan Wang

Dipshika Biswas

Martin Clasby

Mariappan V Cheliah

Duane Burnette

Unmesh Shah

Brian Mckittrick

Thomas Bara

Claire M Lankin

Charles Lee Jayne

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein  and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a &#x3b2;-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

Cyclic amide BACE-1 inhibitors having a benzamide substituent

The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.

HCV NS3 protease inhibitors

The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

Morpholinone compounds as factor IXA inhibitors

The present invention relates to Bicyclic Heterocycle Derivatives, compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.

Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119

The present invention relates to Pyriraidine Derivatives of formula (I), compositions comprising a Pyrimidine Derivative, and methods of using the Pyrimidine Derivatives for treating or preventing obesity, diabetes, a diabetic complication, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G protein-coupled receptor (GPCR) in a patient. 

Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes

Morpholinone compounds as factor IXa inhibitors

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein Ris  R is &#x2014;C(O)&#x2014;N(R)(R) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a &#x3b2;-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

Cyclic amine BACE-1 inhibitors having a benzamide substituent

The present invention relates to novel heterocyclic compounds of Formulae (I): (Chemical formula should be inserted here as it appears on abstract in paper form) Formula (I) as disclosed herein, or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder. 

4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein

Adenosine Areceptor antagonists

Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein

Bicyclic and tricyclic derivatives as thrombin receptor antagonists

The present invention relates to novel heterocyclic compounds of Formulae I-III; as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder. 

Heterocyclic compounds as factor IXA inhibitors

Substituted bicyclic and tricyclic modified himbacine derivative of the formula: or a pharmaceutically acceptable salt or solvate of said compound whereinrepresents an optional double bond and wherein E, F, G, Z, J, X, R, R, R, R, R, R, B and Het are herein defined are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other agents is also claimed.

Substituted bicyclic and tricyclic thrombin receptor antagonists

Fused-ring, heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein

Fused ring thrombin receptor antagonists

A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.

Cannabinoid receptor modulators

Growing community of inventors

Edison, NJ, United States of America

Yan Xia